Why the study?
What is the real-world prescription rate of antithrombotic therapy in patients with non-rheumatic atrial fibrillation who have no contraindications?
What is the real-world prescription rate of antithrombotic therapy in patients with non-rheumatic atrial fibrillation who have no contraindications?
Despite strong evidence supporting anticoagulation for stroke prevention in non-rheumatic atrial fibrillation, a retrospective review found that over half of eligible patients were discharged without antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Low antithrombotic prescribing in eligible non-rheumatic AF patients signals care gaps; leaves open whether targeted interventions improve real-world uptake.
Hendry et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: